Method for on-demand contraception
AssigneesLaboratoire Hra-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsAndre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Claims5
A method for contraception comprising the step of administering 30 mg of ulipristal acetate to a woman more than 72 hours and up to 120 hours after an unprotected intercourse.
Dependencies are inferred from the claim text.